Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03939689|
Recruitment Status : Active, not recruiting
First Posted : May 7, 2019
Last Update Posted : August 4, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a multicenter, randomized, controlled, phase 2 clinical trial designed to evaluate the safety and efficacy of I-131-1095 radiotherapy in combination with enzalutamide compared to enzalutamide alone in participants with prostate-specific membrane antigen (PSMA)-avid metastatic castration resistant prostate cancer (mCRPC) who have progressed on abiraterone. Participants must be chemotherapy-naive and must be ineligible or refuse to receive taxane-based chemotherapy at time of study entry. PSMA-avidity will be determined by central imaging review based on assessment of 18F-DCFPyL PET/CT imaging during screening. Eligible participants meeting the PSMA-avidity criteria will be randomized in a 2:1 ratio to receive either I-131-1095 in combination with enzalutamide (80 participants) or enzalutamide alone (40 participants). An interim analysis for efficacy will be performed after a minimum of 48 evaluable participants have PSA data for at least three months following the first dose of randomized treatment.
All participants will be followed for efficacy, safety assessments, survival status, adverse events of special interest, and new anti-cancer therapy for at least one year or to the end of the study (whichever is later) following the first dose of randomized treatment. Safety data will be monitored by an independent Data Monitoring Committee and the sponsor.
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Prostate Cancer Castration-resistant Prostate Cancer Prostatic Neoplasm Cancer of the Prostate Progressive mCRPC||Drug: I-131-1095 Drug: Enzalutamide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||The study population includes patients with PSMA-avid mCRPC whose disease has progressed despite abiraterone therapy, and are planned for treatment with enzalutamide.|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen (PSMA)-Avid, Chemotherapy-naive, and Progressed on Abiraterone|
|Actual Study Start Date :||May 30, 2019|
|Estimated Primary Completion Date :||June 2023|
|Estimated Study Completion Date :||June 2024|
|Active Comparator: Enzalutamide||
Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
Other Name: Xtandi
|Experimental: I-131-1095 in combination with enzalutamide||
I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) at 75 mCi or 100 mCi each, administered at least 8 weeks apart as determined by dosimetry evaluation and occurrence of dose-limiting events.
Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
Other Name: Xtandi
- PSA Response Rate [ Time Frame: Up to 53 weeks ]The proportion of participants with a PSA response according to PCWG3 criteria defined as the first occurrence of a 50 percent or more decline in PSA from baseline, confirmed by a second measurement at least 3 weeks later.
- Objective Response Rate (ORR) [ Time Frame: Up to 53 weeks ]The proportion of participants who have a partial response (PR) or complete response (CR) based on RECIST 1.1 for soft tissue or PCWG3 for bone (PCWG3-modified RECIST 1.1).
- Radiographic Progression Free Survival (rPFS) [ Time Frame: Up to 53 weeks ]Time from randomization to the first occurrence of radiographic progression based on RECIST 1.1 for soft tissue or PCWG3-modified RECIST 1.1 for bone, respectively, or unequivocal clinical progression, or death on study from any cause.
- Overall Survival (OS) [ Time Frame: Up to 5 years ]Overall Survival is defined as time from randomization to death from any cause.
- PSA Progression [ Time Frame: Up to 53 weeks ]Time from randomization to the date of the first PSA increase from baseline ≥ 25 percent and ≥ 2 ng/ml above nadir confirmed by a second PSA assessment defining progression ≥ 3 weeks later per PCWG3.
- Duration Of Response [ Time Frame: Up to 53 weeks ]Time from the first date of complete response (CR) or partial response (PR) to the first occurrence of radiographic progression based on PCWG3-modified RECIST 1.1, or unequivocal clinical progression.
- Time To Initiation Of Next Treatment For Prostate Cancer [ Time Frame: Up to 5 years ]Time from randomization to initiation of any new treatment for prostate cancer.
- Incidences Of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events As Assessed by CTCAE v5.0 (Safety Outcome Measure) [ Time Frame: After first administration of study drug to visit week 53 ]TEAEs will be summarized by SOC and PT using the frequency and percentage of participants experiencing any adverse event, experiencing each SOC and experiencing each PT within each SOC.
- Adverse Events Resulting In Discontinuation Of Study Drug (Safety Outcome Measure) [ Time Frame: After first administration of study drug to visit week 53 ]A high-level summary of TEAEs will be presented for participants who had at least one TEAE overall, seriousness, and leading to discontinuation of treatment.
- Physical Examination Findings (Safety Outcome Measure) [ Time Frame: At baseline and weeks 9, 17, 25, and 53 ]Percentage of patients with clinically significant abnormal changes on physical examination at weeks 9, 17, 25 and 53 will be presented by treatment group. Clinically significant abnormal physical examination findings will be captured in medical history if prior to study drug treatment.
- Changes In Blood Pressure (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]Percentage of patients with abnormal clinically significant changes in systolic and diastolic blood pressure will be presented by treatment group and visit.
- Changes In Heart Rate (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]Percentage of patients with abnormal clinically significant changes in heart rate will be presented by treatment group and visit.
- Changes In Temperature (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]Percentage of patients with abnormal clinically significant changes in body temperature will be presented by treatment group and visit.
- Shift From Baseline In Selected Clinical Chemistry Laboratory Values At Follow-up (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]Percentage of patients with clinically significant abnormal values of potassium, sodium, magnesium, calcium (corrected) - per CTCAE5, urea and total protein - per investigator assessment will be presented by treatment group.
- Shift From Baseline In Selected Hematology Laboratory Values At Follow-up (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]Percentage of patients with clinically significant abnormal changes in hemoglobin, erythrocytes, thrombocytes, leukocytes, absolute neutrophil count, basophils, eosinophils and monocytes will be presented by treatment group.
- Changes From Baseline In Overall Electrocardiogram (ECG) Assessment At Follow-up (Safety Outcome Measure) [ Time Frame: Baseline and weeks 1, 9, 17, 25, 53 (131-I-1095 + enzalutamide treatment group); Baseline and week 53 (enzalutamide treatment group) ]Percentage of patients with abnormal clinically significant changes on electrocardiogram (ECG) per central reviewer's assessment will be presented by treatment group.
- Summary Of Concomitant Medications (Safety Outcome Measure) [ Time Frame: Baseline to week 53 (concomitant medications); from week 54 up to 5 years (anti-cancer therapies only) ]Medications will be summarized by ATC4 class and generic term using number of participants and percentages by treatment group and overall.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Gender Based Eligibility:||Yes|
|Gender Eligibility Description:||Only male subjects will be enrolled in this study.|
|Accepts Healthy Volunteers:||No|
- Male ≥ 18 years of age
- Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features at initial diagnosis
- Castration-resistant prostate cancer, with serum testosterone ≤ 50 ng/dL at Screening
- Radiographic evidence of metastatic disease prior to Randomization or up to 21 days prior to Screening
Disease progression on prior abiraterone therapy as defined by meeting at least one of the following criteria per the investigator:
- PSA progression as defined by a minimum of two rising PSA levels at least 1 week apart
- Soft tissue disease progression defined by RECIST 1.1
- Bone disease progression defined by two or more new lesions on bone scan
- Planned to receive treatment with enzalutamide
Subjects who are ineligible or choose not to receive taxane-based chemotherapy based on personal preference or physician opinion. Examples of conditions that could make a patient ineligible or refuse to receive taxane-based chemotherapy, but would allow them to still be eligible to receive I-131-1095 include the following:
- Poor performance status
- Prior intolerance to cytotoxic agents
- History of another malignancy suspected for recurrence or metastases
- Other serious medical conditions such as symptomatic peripheral neuropathy CTCAE Grade 2 or higher; or clinically significant cardiovascular disease per the Investigator or treating physician
- Subjects receiving bisphosphonate therapy must have been on stable doses for at least 4 weeks prior to Randomization
- ECOG performance status 0-2
- If sexually active, agree to use a medically acceptable method of birth control or sexual abstinence from the time of dosing through 28 days after the last dose of I-131-1095. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.
- Estimated life expectancy of at least 6 months as determined by the Investigator.
- Able and willing to provide signed informed consent and comply with protocol requirements
- Received any anti-tumor therapy within 4 weeks of Randomization, with the exception of abiraterone, GnRH therapy and non-radioactive bone-targeted agents
- Received prior chemotherapy for castration-resistant prostate cancer
- Superscan as evidenced on baseline bone scan
- Treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 within 6 months prior to Randomization
- Prior hemi-body irradiation
- Prior PSMA-targeted radioligand therapy
- Major surgery within 4 weeks of Randomization
Impaired organ function as evidenced by the following laboratory values at Screening:
- Absolute neutrophil count < 1500 μL
- Platelet count < 100,000/μL
- Hemoglobin < 9.5 g/dL
- Albumin < 3.0 g/dL (30 g/L)
- Total bilirubin > 2 x ULN unless in instances of known or suspected Gilbert's disease
- AST or ALT > 2.5 x ULN
- Calculated creatinine clearance (CrCL) < 30 mL/min (Cockroft-Gault equation), or currently on renal dialysis.
- QT interval corrected for heart rate (QTc) > 470 msec
- Previous use of enzalutamide for more than 7 days prior to consent
- Planned initiation of alternative therapy for prostate cancer, investigational therapy, or participation in clinical trials during the study
- History or risk of seizure (i.e., clinically significant neurological disorder) or any other condition that contraindicates treatment with enzalutamide
- Gastrointestinal disorder affecting absorption of oral medications
- Known or suspected brain metastasis or active leptomeningeal disease
- Active malignancy other than prostate cancer, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or non-muscle invasive bladder/urothelial cancer
- Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completing the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03939689
|Study Director:||Jean-Claude Provost, MD||Progenics Pharmaceuticals, Inc.|
|Responsible Party:||Progenics Pharmaceuticals, Inc.|
|Other Study ID Numbers:||
|First Posted:||May 7, 2019 Key Record Dates|
|Last Update Posted:||August 4, 2022|
|Last Verified:||August 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
adjunct radiation therapy
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male
Male Urogenital Diseases